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1. Introduction 
Prostate cancer (PC) is the second most frequent malignant disease and the second-leading 
cause of cancer deaths among men in the United States (1). Both evidence and epidemiologic 
studies  have shown that PC is rare in men younger than 50 years of age, but thereafter the 
risk of incident prostate cancer increases significantly with increasing age (2). After the 
introduction and widespread use of the prostate-specific antigen (PSA) blood test, PC 
incidence has increased and it is expected that this disease is likely to become a more 
prominent and pressing problem in many countries as the percentage of elderly men 
increases (3). Actually declines in mortality at younger ages, medical advances, and better 
health care have resulted in longer life expectancy in both the developing and the developed 
world the last three decades. Statistics compiled by the United Nations showed that in 1999, 
10% of the world population was 60 years and older (4). By 2050, this percentage will rise to 
22%. In Hong Kong, where the proportion of elderly is even higher, it is estimated to rise to 
40%. Regarding male gender, the population over 65 years is expected to increase 4-fold 
worldwide by 2050 (5). Achievements of the 20th century have changed the world’s 
demographic proportions without altering the epidemiology of PC. Indeed, PC still remains 
a disease of elderly men and thus, increased PC incidence could be partly attributed to the 
steadily growing ageing population (6).  
While the majority of elderly PC patients in the past were diagnosed with local advanced or 
metastatic disease, a rising number of elderly men are now diagnosed with early stage PC. It 
is not known whether and if this is due to the effective utilization of health care resources or 
to the widespread use of PSA testing worldwide. Several studies however showed that after 
the introduction of PSA, additionally to the increase in the PC detection rate, an eventual 
shift towards earlier pathological stage was occurred also (3). The increased life expectancy 
enjoyed by the world population also means that the life span beyond age 60 is much longer 
than demographers have previously envisaged. Currently, a large proportion of the 
population remains active beyond the age of 70 and lives beyond the age of 80. Since many 
of them are healthy, the number of elderly men who will be diagnosed with PC and may 
require treatment will further increase in the coming years (7).  
The aim of present study is to discuss the issue of screening for PC in elderly individuals as 
well as to review the current data on the treatment of early stage PC in elder males. A 
secondary aim is to examine whether or not advanced age impacts on PC risk. The impact of 
life expectancy on the choice of treatment in both patients and health care providers has 
been investigated also.  
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2. Methods 
We identified studies published from 1990 onwards by searching the MEDLINE database of 
the National Library of Medicine. Initial search terms were localized prostate cancer, early 
stage prostate cancer, combined with elderly patients, life expectancy, palliative, curative, 
quality of life, watchful waiting, radical prostatectomy, brachytherapy and external beam 
radiotherapy. References in the selected publications were checked for relevant publications 
not included in the Medline/Pubmed search.  
3. Results 
3.1 How ageing can increase the risk of prostate cancer? 
A definitive cause of PC has not been identified and the specific mechanisms that lead to the 
development of the disease are still unknown. Although several risk factors have been 
proposed, the only risk factors that can be considered established are age, race and family 
history. Evidence suggests that an association between the above risk factors through a 
common pathogenic mechanism exists. On one hand, development and function of the 
prostate gland is endocrine controlled and androgen/estrogen synergism is necessary for 
the integrity of the normal human prostate. On the other hand androgen action is critical to 
the development, progression and cure of PC. Under those circumstances, it could be 
expected that ageing facilitate PC development through androgenic action. In fact, 
androgens undergo a significant age-dependent alteration: with ageing the production of 
testosterone by the testes is decreasing leading thus in a significant reduction of the 
endogenous testosterone levels. DHT activity decreases in the epithelium while in the 
stroma it remains constant over the whole age range. The age-dependent decrease of the 
DHT accumulation in epithelium and the concomitant increase of the estrogen accumulation 
in stroma lead to a tremendous increase of the estrogen/androgen ratio in the human 
prostate. Although, the specific pathway remains partially investigated, it is widely 
accepted that these alterations promote the initiation of benign prostatic hypertrophy, the 
most common disease of the ageing prostate. Similarly to benign prostatic hypertrophy, PC 
incidence increases with age: it seldom develops before the age of 40 and is chiefly a disease 
found in men over the age 65 years. Epidemiological evidence from autopsy studies show 
that while a very high proportion of elderly men has histological evidence of the disease, a 
much smaller proportion actually develop clinically apparent PC however, most of the 
impalpable cancers likely to progress and become clinically significant (advanced Gleason 
score, greater volume) are found in older individuals (8). However, age-related increase in 
the prevalence of prostate cancer found in autopsy is not similar worldwide. Variations in 
the reported incidence of PC between different racial groups suggest that some populations 
are either more susceptible to PC-promoting events or are exposed to different promoting 
agents (9). Take the above in consideration it could be speculated that ageing may promote 
clonal transformation events of pathogenetic importance for the initiation of PC. These 
clonal transformation events may be boosted by genetic predisposing factors. Although the 
exact pathways remain unknown, evidence suggests that they involving the androgen 
receptor (AR). The AR is a structurally conserved member of the nuclear receptor 
superfamily and signalling via the AR is critical for carcinogenesis and progression of the 
disease. The AR´s amino-terminal domain is required for transcriptional activation and 
contains a region of polyglutamine encoded by CAG trinucleotide repeats. As androgen 
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influences prostate cancer growth, expansion of CAG repeats in the AR affect the risk of 
developing prostate cancer in a race and age depending matter  (10).  
Age-dependent clonal transformation events that affect the risk of developing prostate 
cancer may also occur to the Insulin-like Growth Factor-II (IGF-II) gene. The IGF-II gene is 
an auto- paracrine growth stimulator that is an important positive modulator of cancer 
development. IGF-II losses of imprinting, as well as increased lGF-II expression resulting 
from age-dependent changes in DNA methylation, have been recently associated with 
increased risk for PC development (11). 
3.2 The issue of screening for prostate cancer in elderly individuals 
A major consideration for cancer screening is to weigh up the possibility someone will have 
needless treatment against saving lives. PC can develop into a fatal, painful disease, but it 
can also develop so slowly that it will never cause problems during the man's lifetime. 
Actually, although none of the existing screening tools can accurately distinguish between 
lethal and indolent PC, the use of PSA has been shown to increase the PC detection rate with 
a shift to detection at earlier and therefore curable stages (12). This fact generated also 
concerns about over-diagnosis and over-treating and arguments both for and against the 
efficacy of screening. Under the light of this evidence it became clear why the issues of over-
diagnosis and over-treating are of outmost importance when deciding to screen elderly 
individuals (13).  
Data from US Cancer of the Prostate Strategic Urological Research Endeavor shows that 
most of the patients diagnosed with prostate cancer the last two decades in the US had low 
or intermediate disease at diagnosis (14). Moreover, between 20 and 30% of PCs found in 
radical prostatectomy specimens of men with PSA-detected disease are non palpable, 
potentially indolent cancers (Gleason <6, tumor volume <0,5cm3) (15,16). Since doubling time 
of high and intermediate differentiated prostatic carcinomas reaches 7 and 5 years 
respectively, a small tumor (<0,5cm3) poses little threat for the life of older individuals 
(from the perspective that needs enough time to became life threatening). In confirmation to 
the above, Albertsen and colleagues demonstrated that men with prostate biopsy specimens 
showing Gleason score 2 to 4 disease faced a minimal risk of death from prostate cancer 
within 15 years from diagnosis (17). Given that life expectancy of American males at the age 
of 65 is 16 years (18) and the mean time to cancer-specific death of apparently clinically 
localized prostate cancer is 17 years (19), it became obvious why PC screening and treatment 
of PSA detected PCs in elderly patients is a controversial issue. Most doctors however argue 
against PSA testing for men who are in their 70s or older, because even if prostate cancer 
were detected, most men would be dead of something else before the cancer progressed (20). 
This is true only in part. As previously mentioned, today a large proportion of the 
population lives beyond age 70 and many are healthy. These men have several reasons –the 
belief in the benefit of early diagnosis, the need to have trust, and a desire for reliable 
screening resembling women- to undergo testing for prostate cancer. Yet, patient’s anxiety 
increase the likelihood of getting the screening test, by acting powerfully on the screening 
decisions of physicians, whose clinical judgment would otherwise make them least, inclined 
to order the test (21).  
At the moment, PC screening is being performed unofficially in elderly patients visiting 
outpatient departments of general hospitals and consulting rooms. The exact magnitude of 
this opportunistic screening is not known however it is believed that reaches high numbers 
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worldwide. Hoffman and associates and Walter and colleagues found a 56% and 50% PSA 
screening rate in their cohort of elderly men in 2003 and 2010, respectively (22,23). Bowen and 
co-workers found that PC screening rates among men at the age of 80 and older are even 
higher than that of men in the age range of 50 to 64 years (64% versus 56%)(24). Similarly, in 
a study by D’Ambrosio and colleagues, the highest yearly exposure to PSA screening and 
the highest frequency of repeat testing were observed in the age range of 70 to the 79 years 
(25). In contrast, Zeliadt and associates demonstrated that PSA testing among men older than 
75 years has declined slightly following the recommendations by the US Preventive Services 
Task Force in 2008 and is still continuing to decline (15). Aus and colleagues found that 
restrictions in the use of PSA test in individuals over 75 years resulted in PC incidence falls 
after peaking at the age of 75 (26). Interestingly, evidence suggests that PSA testing may be 
useful in diagnosis of aggressive early PC in a subset of elderly patients. A current study by 
Brassell and colleagues showed that as men age, parameters consistent with more 
aggressive disease become more prevalent (27) a fact that was confirmed by the findings of 
an autopsy study demonstrating that a proportion of elderly men with histologically 
apparent disease may develop lethal PC (21). Therefore it is not surprising that older 
individuals with clinically apparent PC usually die from PC. These data may have 
implications for future screening and treatment recommendations. Currently, age plays an 
important role in both screening decision and treatment choice and thus elderly patients are 
less likely to undergo PSA test and receive local therapy.  
Data from US Cancer of the Prostate Strategic Urological Research Endeavor shows a 
significant reduction of risk of death from metastatic prostate cancer and a decrease in 
prostate carcinoma-specific mortality the last two decades in the US (14). As yet it is not 
possible to say what proportion of the fall in mortality is the result of improvements in 
treatment, changes in cancer registration coding, the attribution of death to PC, and the 
effects of PSA testing. Accumulative evidence however suggests that early screening of PC 
in asymptomatic men reduce their risk of death from metastatic disease. Interestingly, the 
recently published results of the European Randomised Study for Screening of Prostate 
Cancer (ERSPC) reported a relative PC mortality reduction of at least 20% by PSA-based 
population screening (28) while Goel and Kopec reported an even higher reduction of risk of 
death from metastatic PC among men who were not screened regularly as part of a 
screening program (29). 
Given that PSA screening mainly diagnoses early PC, it may be justifiable for otherwise 
healthy elderly men to undergo PSA test. This is of outmost importance since older patients 
are more likely to have high-risk prostate cancer at diagnosis and lower overall survival. In 
fact, under-use of potentially curative local therapy among older men with high-risk disease 
may explain, at least in part, the observed differences in cancer-specific survival across age 
strata.(30). Taking in consideration these findings along with observations of Brassell and co-
workers (27) it became obvious that evidence supports making decisions regarding 
screening on the basis of disease risk and life expectancy rather than chronologic age.  
Currently, no standard recommendation for PC screening exists. Recently, the American 
Urological Association recommends PC screening to men aged 40 years or older. In contrast, 
screening is presently discouraged by the EC Advisory Committee on Cancer Prevention for 
its negative effects are evident and its benefits still uncertain (31). According to the U.S. 
Preventive Services Task Force, evidence is insufficient to recommend in favour of, or 
against routine PC screening (23). The abovementioned professional organizations and 
health agencies as well as most of medical experts agree that it is important that the benefits 
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and risks of diagnostic procedures and treatment be taken into account when considering 
whether to undertake PC screening. On the other hand, treatment recommendations are 
now recognizing that older men with PC should be managed according to their individual 
health status, which is mainly driven by the severity of associated comorbid conditions, 
and not according to chronological age. According to the International Society of Geriatric 
Oncology Prostate Cancer Task Force, it is possible, based on a rapid and simple 
evaluation, to classify patients into four different groups: 1) “Healthy” patients 
(controlled comorbidity, fully independent in daily living activities, and no malnutrition) 
should receive the same treatment as younger patients; 2) “Vulnerable” patients 
(reversible impairment) should receive standard treatment after medical intervention; 3) 
“Frail” patients (irreversible impairment) should receive adapted treatment; 4) Patients 
who are “too sick” with “terminal illness” should receive only symptomatic palliative 
treatment.(30) The same rapid and simple evaluation may help physicians who perform 
PSA screening to decide who to screen. 
3.3 Treatment options and treatment decision making 
The main treatment options include radical prostatectomy (RP), radiotherapy (external 
beam radiotherapy and brachytherapy), watchful waiting (WW) and androgen deprivation 
therapy (ADT). Other include, cryotherapy (freezing the prostate), high-intensity focused 
ultrasound (HIFU), radiofrequency interstitial tumour ablation (RITA) and non-hormonal 
therapy (cytotoxic agents). Radical prostatectomy, brachytherapy and external beam 
radiotherapy are considered curative, while watchful waiting and hormone-therapy 
palliative. All treatments have risks of complications, although frequency and severity may 
vary. The primary goal of treatment is to target the men most likely to need intervention in 
order to prevent prostate cancer death and disability while minimizing intervention-related 
complications. However, whereas the standard oncologic evaluation works reasonably well 
in most other populations, in elderly PC patients, tends to overestimate possible harms 
associated with radical treatment and underestimate patients ability to withstand treatments 
side effects. In accordance to the above, various studies have demonstrated that potentially 
curative therapy (radical prostatectomy or radiotherapy) is applied less often in older PC 
patients (32,33,34,35,36). Traditionally, PC is considering a slow progressive disease that needs 
enough time to become life threatening for an elder individual and this possibly explains the 
above observation. However, a multivariate analysis of the SEER database revealed 
significantly decreased odds of receiving cancer directed surgery in the elderly patient with 
lung, liver, breast, pancreas, esophageal, gastric cancers, sarcoma and rectal cancer while 
other studies have demonstrated under use of cancer directed radiation and chemotherapy 
(37,38,39). These findings are posing justifiable concern about under-treatment of the elderly 
cancer patient and raise the provocative question if this is due to judicious, evidence based 
selection or discrimination based only on age (40). The reasons for the observed under use of 
cancer directed treatment in the elderly remain elusive. However, discrimination -if present- 
reflects the stereotypes that older people are physically frail, unfit for curative treatment, 
indisposed to accept treatment related complications, impatient and uninterested in 
prolonging survival. With regard to PC treatment decision making, increasing age is 
definitely a risk factor for receiving inadequate treatment (41). Harlan et al demonstrated 
that advantaged age is- still- considering as important as PSA, clinical stage and Gleason 
score while other demonstrated that age is the predominant factor influencing treatment 
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decision making: Alibhai and colleagues generated an age-stratified random sample of 347 
men from a cohort of patients with newly diagnosed prostate carcinoma in the Ontario 
Cancer Registry. Patients who were younger than 60 years were more likely to receive 
radical prostatectomy than radiation therapy or no therapy. Men between 60 and 69 years of 
age were more likely to receive radiation therapy than radical prostatectomy. Men between 
70 and 79 years were most likely to receive no therapy, and nearly all men over 80 years 
received no therapy (42). Basically, although age plays a key role in treatment decision 
making, age itself is not predictive of outcome in an elderly cancer patient. In contrast, 
treatment outcome is strictly associated with clinical parameters such as the tumor stage, 
tumor grade or Gleason score and PSA level and therefore, treatment selection should be 
balanced between clinical stage and remaining life expectancy. It should be noticed however 
that the 10-year rule currently used to estimate life expectancy in elderly PC patients has 
demonstrated limited predictive validity and its use in clinical decision-making doesn’t 
decrease the likelihood of receiving inappropriate treatment in elderly individuals (31).  
Regarding localized PC, available treatment options include established therapies such as 
WW, RP, brachytherapy and external beam radiotherapy and non established therapies such 
as minimal invasive techniques and early hormone-therapy (43). RP is considering the gold 
standard for the treatment of localized PC and in fact it is the most common treatment with 
approximately 60,000 operations performed annually in the US (44). However, only a small 
number of elderly patients with early stage PC are treated with RP (45). The reason why 
advanced age is an unfavorable predictor of the probability of surgical treatment is not 
known (46). Actually, the fact that elderly individuals have lower life expectancy as well as 
the belief that elderly patients with localized disease are considering more prone to die with 
PC than of it, partly explain why PR is the less popular treatment of early PC in elderly 
patients. Moreover, elderly patients are often being considering fragile enough to receive 
surgical treatment. Whether and if age increase surgical risk is a controversial issue and for 
this reason several investigators claim that it is co-morbidity that actually increases the 
surgical risk and not ageing itself (47). Although, co-morbid illness has demonstrated 
increasing importance as a prognostic factor, its role is poorly defined. It is generally 
accepted that co-morbidity limits the generalization of results to older and sicker patients 
however; the widespread integration of co-morbidity into clinical practice has yet to be 
realized.  
Reported differences in PC specific survival across age strata may be associated with under 
use of potentially curative local therapy among older men. In fact, PC mortality increases 
with ageing, peaks at the age of 70-75 and no significant decrease occurs thereafter (table 1). 
According to the SEER database, younger men (under age 65) with localized prostate cancer 
had 25-year prostate cancer mortality rates of approximately 19% for Gleason 6 disease, 37% 
for Gleason 7 disease, and 50% for Gleason 8-10 disease (48). Given that the survival 
advantage of surgery is most pronounced in men with higher stage disease, it became 
obvious that elderly PC patients with aggressive disease and life expectancy >10 years are 
likely to die from progressive prostate cancer (49). Worth mentioning, Bechis et al. studied 
men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) 
database with complete risk, treatment, and follow-up information. They found that older 
patients are more likely to have high-risk prostate cancer at diagnosis and less likely to 
receive local therapy (30). In confirmation to the above, Dahm et al.showed that risk of death 
from PC for elderly PC patients treated with PR is significantly lower when compared with  
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AGE DEATHS % RATE 
15-19 0 0 
20-24 1 0,0 
25-29 2 0,0 
30-34 1 0,0 
35-39 4 0,0 
40-44 20 0,1 
45-49 71 0,3 
50-54 233 0,9 
55-59 722 2,8 
60-64 1738 6,9 
65-69 3123 12,5 
70-74 4636 18,5 
75-79 5337 21,4 
80-84 4536 18,2 
> 85 4625 18,1 
Table 1. Age and PC specific mortality (US Public service 1989).  
that of elderly PC patients treated with watchful waiting (50). Results from other studies 
showed that surgical therapy can achieve excellent oncologic results in selected elderly 
patients but they didn’t found significant differences in overall survival (51,52). According to 
the results of the Scandinavian Prostate Cancer Group (SPCG) study, radical prostatectomy 
is associated with less deaths from prostate cancer  (10 vs.15%), less deaths from any other 
cause (24 vs. 30%) and less metastases (14 vs. 23%) in a median follow-up of 8.2 years. 
However, benefit in cancer specific survival is limited to patients younger than 65 years.  
On the other hand there are several facts supporting WW (deferring intervention until the 
advent of symptoms) as an ideal treatment of early PC in elderly patients: Epidemiological 
evidence from autopsy studies show that while a very high proportion of elderly men has 
histological evidence of the disease, a much smaller proportion actually develop clinically 
apparent PC (53). Several authors demonstrated that elderly patients with localized PC have 
a favorable outlook following WW (54,55) and other showed that WW results in similar 
overall survival when compared with RP (56). In a pooled analysis of 828 case records from 
six nonrandomized studies, of men treated conservatively for clinically localized prostate 
cancer, Chodak et al, found an impressive 87% five years disease-specific survival rate (57), 
however other found that disease specific survival is better in patients who had undergone 
surgery and some authors argue that WW simply postpone the final treatment (58,59,60,61).  
Notably, there are no randomized clinical trials comparing surgery with radiation therapy 
in elderly PC patients, however an observational study, by Albertsen and colleagues 
showed that surgery is superior to radiation in localized prostate cancer in terms of 
prolonging overall and disease-specific survival (62). 
The truth is that the preferred management of clinically localized prostate cancer is not 
known, due in large part to the paucity of randomized controlled trials comparing the 
effectiveness and harms across primary treatment options. It seems that age itself is the 
main determinant of treatment selection: according to the Swedish Cancer Register in men 
with localized tumors expectant treatment was much more commonly used in those aged > 
or =75 years than in those aged <75 years (63). It is also clear that WW is an adequate 
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approach for the treatment of early stage PC in patients suffering of live threatening 
diseases, unfit for radical treatment, however, it remains unclear whether and if treatment 
can be delayed until absolutely necessary with no detriment to curability in otherwise 
healthy elderly PC patients. Interestingly, Wong et al found no survival advantage 
associated with expectant treatment for localized PC in elderly men aged 65 to 80 years (64). 
Certainly observational data cannot completely adjust for potential selection bias and 
confounding, however these results clearly shows that specific factors other than tumor 
stage may contribute to WW failure. Given that PC exhibits a wide range of biologic 
behaviour, it could be assumed that disease specific survival outcomes in patients with 
localised PC following WW are associated with Gleason score or baseline PSA level: In the 
study of Johansson, only the 6% of patients with well differentiated PC, died of PC while 
mortality rates for intermediate and poorly differentiated cancers were 17% and 56% 
respectively (54). Soloway and associates reported an 85% treatment-free rate at 5 years on a 
small cohort of patients diagnosed with 'low-risk' prostate cancer managed by WW (65). 
Sandblom et al found also a great influence on survival and suggest the grade of malignancy 
to be taken into account when deciding on therapy (55).  
The major risk of watchful waiting is that without treatment, prostate cancer can grow and 
spread outside the prostate capsule. In fact, even small, slow-growing tumors may become 
rapidly growing tumors and sometimes prostate cancer that appears to be small and slow 
growing may be larger and more aggressive than originally thought. Identification of 
patients who have a low probability of disease progression could be based on strict clinical 
and pathologic criteria such as Gleason score of 6 or less, a PSA level of 10 ng/ml or less, 
and stage T1c–T2a disease (66). Again, although patients with these characteristics have a 
much more favourable natural history and progression rate than those who have a higher 
Gleason grade or PSA level, in a substantial proportion of men tumours will still progress to 
advanced, incurable prostate cancer and death (67). 
These data suggest that it is of outmost importance to distinguish between patients who are 
at higher risk and need active therapy and patients who are at low risk for disease 
progression and support making decisions regarding treatment on the basis of disease risk 
and life expectancy rather than on chronologic age (68,69).  
It therefore became clear that a comprehensive health status assessment is the key in 
distinguishing between frail and healthy elderly patients and in developing appropriate 
management approaches for these individuals. The geriatric assessment differs from a 
standard medical evaluation as it focuses on elderly individuals with complex problems and 
emphasizes functional status, co-morbidity and quality of life. Most importantly, 
comprehensive geriatric assessment frequently takes advantage of an interdisciplinary team 
of providers (urologists, radiation oncologists, medical oncologists and geriatricians). 
Recently, the SIOG has developed a proposal of recommendations in this setting based on a 
systematic bibliographical search focused on screening, diagnostic procedures and 
treatment options for localised, locally advanced and metastatic prostate cancer in senior 
adults. Specific aspects of the geriatric approach were emphasised, including evaluation of 
health status (nutritional, cognitive, thymic, physical and psycho-social) and screening for 
vulnerability and frailty (70). According to the above elderly PC patients are classified in 4 
groups. In Group 1 (no abnormality), patients are ‘fit’ and should receive the same treatment 
as younger patients; patients in Group 2 (one impairment in IADL or one uncontrolled 
comorbidity or at risk of malnutrition) are ‘vulnerable’ and should receive standard 
treatment after medical intervention; patients in Group 3 (one impairment in ADL or more 
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than one uncontrolled comorbidity or severe malnutrition) are ‘frail’ and should receive 
adapted treatment; patients in Group 4 (dependent) should receive only symptomatic 
palliative treatment (32).  
4. Conclusions 
Actually, health status is more reliable prognostic factor for survival and treatment related 
outcomes in oncology than patient age and with this modern approach should be adapted in 
order to screening senior adults. Age, PSA level, histological grade, and comorbidities 
should be carefully balanced before making a treatment decision, in elderly men suffering 
from prostate cancer. Elderly men with limited life expectancy due to other significant life-
limiting medical conditions, such as chronic obstructive pulmonary disease and advanced 
coronary artery disease, are less likely to benefit from aggressive treatment and are 
candidate for a palliative approach Therefore, it is reasonable to withhold early detection 
through PSA screening in these patients thus avoiding the associated risks and impact on 
quality of life. In selected cases of healthy elderly patients and long life expectancy, PSA 
screening and curative treatment of undifferentiated prostate cancers could be considered as 
a rational choice. 
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